JO
KRYS icon

John Overdeck’s Krystal Biotech KRYS Stock Holding History

John Overdeck’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$483K Buy
+1,300
New +$388K ﹤0.01% 4186

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

John Overdeck's KRYS Position: Q2 2026 in Review

John Overdeck opened a new position in Krystal Biotech (KRYS) in Q2 2026: 6,084 shares worth $2.26M. The stake represents ﹤0.01% of the portfolio and ranks #2884 among its holdings. This is a return to the name: John Overdeck previously reported a position in KRYS as recently as Q3 2021.

John Overdeck first reported a position in KRYS in Q2 2020 and has held it in 3 quarters since. 420 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • John Overdeck held 6,084 shares of Krystal Biotech worth $2.26M as of Q2 2026.
  • Krystal Biotech was a new John Overdeck position in Q2 2026.
  • Krystal Biotech made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2884 holding.
  • John Overdeck first reported a position in Krystal Biotech in Q2 2020 and has held it in 3 quarters since.
  • 420 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.